<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>心血管出版物</title><link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc =20 230708114047&amp;utm_campaign=pubmed-2&amp;utm_medium=rss&amp;v=2.17.9.post6+86293ac&amp;utm_source=Chrome&amp;ff =20230921221526<description>心血管亮点：PubMed 的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;utm_medium=rss&amp;v=2.17.9.post6+86293ac&amp;utm_source=Chrome&amp;ff=20230921221526" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS 源 (2.17.9.post6+86293ac)</generator><language> zh</language><lastbuilddate> 2023 年 9 月 22 日星期五 02:15:26 +0000</lastbuilddate><pubDate> Thu, 21 Sep 2023 06:00:00 -0400</pubDate><ttl> 120</ttl><item><title>人类诱导多能干细胞来源的心肌细胞和内皮细胞的联合治疗使小鼠和非人类灵长类动物的梗塞心脏再生</title><link/>https://pubmed.ncbi.nlm.nih.gov/37732466/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230921221526&amp;v=2.17.9.post6+86293ac<description>结论：这些结果证明了将 iPSC 衍生的 EC 和 CM 相结合用于治疗心肌梗死后心脏的协同效应，为临床转化提供了一种有前途的策略。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 9 月 21 日。doi：10.1161/CIRCULATIONAHA.122.061736。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：将人诱导多能干细胞（hiPSC）来源的心肌细胞（CM）进行细胞移植后，可以实现哺乳动物心脏的再肌化，但在临床实践中仍存在一些障碍。血管形成，致命性心律失常发生的可能性与未成熟 CM 的胎儿细胞样性质有关。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：我们从 3 个独立供体中生成了 3 系 hiPSC 衍生内皮细胞 (EC) 和 hiPSC-CM，并在与 EC 共培养中测试了 hiPSC-CM 肌节长度、间隙连接蛋白和钙处理能力。 hiPSC-EC 和 hiPSC-CM 联合移植对心肌梗死 NOD-SCID 小鼠（n≥4）的治疗效果。通过超声心动图评估心功能，同时使用 3 导联心电图记录心律失常事件。我们进一步使用健康非-人类灵长类动物（n = 4）注射细胞，通过组织学分析研究移植的 hiPSC-CM 的细胞植入、成熟和整合，单独或与 hiPSC-EC 一起。最后，我们测试了缺血再灌注损伤中的细胞疗法在非人类灵长类动物中（EC+CM、CM 和对照分别为 4、3 和 4）。通过超声心动图和心脏 MRI 评估心脏功能，而通过遥测心电图记录仪监测心律失常事件。细胞植入，还研究了血管生成和人体移植物的宿主-移植物整合。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：我们证明人 iPSC-EC 在体外和体内均可促进 hiPSC-CM 的成熟和功能。当与 EC 共培养时，CM 在细胞结构和功能方面表现出更成熟的表型。在小鼠模型中，共移植增强了 EC-伴随移植物血管化，促进梗死区CM的成熟，改善心肌梗死后的心功能。此外，在非人灵长类动物中，EC和CM的移植显着增强了移植物的大小和血管系统，改善了缺血再灌注后的心功能。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：这些结果证明了将 iPSC 衍生的 EC 和 CM 相结合用于治疗心肌梗死后心脏的协同效应，为临床转化提供了一种有前途的策略。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37732466/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230921221526&v=2.17.9.post6+86293ac">37732466</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.122.061736>10.1161 / CIRCULATIONAHA.122.061736</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37732466</guid><pubDate> Thu, 21 Sep 2023 06:00:00 -0400</pubDate><dc:creator>郑育哲</dc:creator><dc:creator>谢家文</dc:creator><dc:creator>林珍菊</dc:creator><dc:creator>张敏迪</dc:creator><dc:creator>黄静英</dc:creator><dc:creator>莱利·庞特尼</dc:creator><dc:creator>艾米吴梅</dc:creator><dc:creator>丁建宇</dc:creator><dc:creator>郑达连 陈先生</dc:creator><dc:creator>马丁·W·尼科尔森</dc:creator><dc:creator>林宝如</dc:creator><dc:creator>陈鸿志</dc:creator><dc:creator>吉娜·C·金</dc:creator><dc:creator>张建华</dc:creator><dc:creator>詹妮弗·库南</dc:creator><dc:creator>普加巴苏</dc:creator><dc:creator>希瑟·西蒙斯</dc:creator><dc:creator>刘彦文</dc:creator><dc:creator>蒂莫西·黑客</dc:creator><dc:creator>蒂莫西·坎普</dc:creator><dc:creator>谢长荣</dc:creator><dc:date>2023-09-21</dc:date><dc:source>循环</dc:source><dc:title>人类诱导多能干细胞来源的心肌细胞和内皮细胞的联合治疗使小鼠和非人类灵长类动物的梗塞心脏再生</dc:title><dc:identifier>下午：37732466</dc:identifier><dc:identifier> doi:10.1161/循环AHA.122.061736</dc:identifier></item><item><title> LAAOS III 中口服抗凝药的使用和左心耳封堵术</title><link/>https://pubmed.ncbi.nlm.nih.gov/37732457/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230921221526&amp;v=2.17.9.post6+86293ac<description>结论：无论患者是否接受 OAC，左心耳封堵术的益处都是一致的。左心耳封堵术可以减少患者的血栓栓塞，而与是否使用 OAC 无关。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 9 月 21 日。doi：10.1161/CIRCULATIONAHA.122.060315。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：LAAOS III（左心耳封堵研究 III）表明，左心耳 (LAA) 封堵会增加接受心脏手术的心房颤动患者发生缺血性卒中或全身性栓塞的风险。本文根据左心耳 (LAA) 封堵对减少卒中的影响进行了研究。口服抗凝剂（OAC）使用的变化。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：在每次随访时收集有关 OAC 使用的信息。调整比例风险模型，包括使用随机化后 1 和 2 年的出院标志，评估左心耳封堵对缺血性中风或全身性栓塞风险的影响，根据整个研究中 OAC 的使用情况，还进行了调整比例风险模型，以 OAC 的使用作为时间依赖性协变量，以评估左心耳封堵的效果。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：出院时，3027 名患者（63.5%）正在接受维生素 K 拮抗剂治疗，879 名患者（18.5%）正在接受非维生素 K 拮抗剂口服抗凝剂（直接 OAC），治疗组之间 OAC 使用情况没有差异。有 2887 名（60.5%）名患者在所有随访中都接受了 OAC，1401 名（29.4%）名患者在某些访视中接受了 OAC，472 名（9.9%）名从未接受过 OAC。所有 3 组出院后缺血性卒中或全身性栓塞均一致：风险比分别为 0.70 (95% CI, 0.51-0.96)、0.63 (95% CI, 0.43-0.94) 和 0.76 (95% CI, 0.32-1.79)以 OAC 作为时间依赖性协变量的调整比例风险模型表明，无论患者是否接受 OAC，左心耳封堵术对卒中或全身性栓塞的减少程度相似。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：无论患者是否接受 OAC，左心耳封堵术的益处都是一致的。左心耳封堵术可以减少患者的血栓栓塞，而与是否使用 OAC 无关。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37732457/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230921221526&v=2.17.9.post6+86293ac">37732457</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.122.060315>10.1161/循环AHA.122.060315</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37732457</guid><pubDate> Thu, 21 Sep 2023 06:00:00 -0400</pubDate><dc:creator>斯图尔特·J·康诺利</dc:creator><dc:creator>杰夫·希利</dc:creator><dc:creator>埃米莉·P·贝利-科特</dc:creator><dc:creator>库马尔·巴拉苏布拉曼尼安</dc:creator><dc:creator>多梅尼科·帕帕雷拉</dc:creator><dc:creator>凯瑟琳·布雷迪</dc:creator><dc:creator>威尔科·雷恩茨</dc:creator><dc:creator>伯恩哈德·C·丹纳</dc:creator><dc:creator>P·J·德弗罗</dc:creator><dc:creator>穆库尔·夏尔马</dc:creator><dc:creator>钦塔尼·拉马桑达赫蒂格</dc:creator><dc:creator>萨利姆·优素福</dc:creator><dc:creator>理查德·P·惠特洛克</dc:creator><dc:date>2023-09-21</dc:date><dc:source>循环</dc:source><dc:title>LAAOS III 中口服抗凝药的使用和左心耳封堵术</dc:title><dc:identifier>下午：37732457</dc:identifier><dc:identifier> doi:10.1161/循环AHA.122.060315</dc:identifier></item><item><title>现有的非门控 CT 冠状动脉钙可预测接受非心脏手术的患者的手术风险 (ENCORES)</title><link/> https://pubmed.ncbi.nlm.nih.gov/37732454/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230921221526&amp;v=2.17.9.post6+86293ac<description>结论：从现有非门控胸部 CT 成像获得的冠状动脉钙化的患病率和严重程度改善了非门控手术前的术前临床风险分层。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 9 月 21 日。doi：10.1161/CIRCULATIONAHA.123.064398。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：非心脏手术前的术前心血管风险分层是一个常见的临床挑战。心电门控胸部计算机断层扫描 (CT) 成像的冠状动脉钙化评分与围手术期事件相关。在术前评估时，许多患者不会进行心电图检查门控胸部 CT 成像，但将对各种非心脏适应症进行非门控胸部 CT 研究。我们评估了根据之前的非门控胸部 CT 成像估计的冠状动脉钙化严重程度与非心脏手术后围手术期主要临床事件 (MCE) 之间的关系。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：我们回顾性地确定了 2016 年至 2020 年在由 4 个急症护理中心组成的大型学术医疗系统中接受过院内大型非门控手术的连续成年人，年龄≥45 岁。所有患者均进行了非门控（造影或非造影）胸部 CT 成像术前 1 年内，由不了解临床数据的医生使用 0 至 3 级（缺如、轻度、中度、重度）对每根血管中的冠状动脉钙从缺如到重度进行回顾性分级。计算估计的冠状动脉钙负荷 (ECCB)作为每条冠状动脉的评分总和（0 至 9 级）。计算每位患者的修订心脏风险指数。围手术期 MCE 定义为手术后 30 天内的全因死亡或心肌梗死。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：共纳入 2554 名患者（中位年龄 68 岁；49.7% 女性；中位修订心脏风险指数为 1）。从非门控胸部 CT 成像到非门控手术的中位时间间隔为 15 天（四分位数间距，3- 106 天）。中位 ECCB 为 1（四分位距，0-3）。136 例（5.2%）患者发生围手术期 MCE。较高的 ECCB 值与围手术期 MCE 逐步增加相关（0：2.9%，1- 2：3.7%，3-5：8.0%；6-9：12.6%， <i>P</i> &lt;0.001）。将 ECCB 添加到具有修订的心脏风险指数的模型中，改善了 MCE 的 C 统计量（从 0.675 到 0.712， <i>P</i> =0.018 ），净重分类改善为 0.428（95% CI，0.254-0.601， <i>P</i> &lt;0.0001）。ECCB ≥3 与 ECCB &lt;3 相比，MCE 调整后赔率高出 2 倍（调整后赔率， 2.11 [ 95% CI，1.42-3.12]）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：从现有非门控胸部 CT 成像获得的冠状动脉钙化的患病率和严重程度改善了非门控手术前的术前临床风险分层。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37732454/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230921221526&v=2.17.9.post6+86293ac">37732454</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064398>10.1161/循环AHA.123.064398</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37732454</guid><pubDate> Thu, 21 Sep 2023 06:00:00 -0400</pubDate><dc:creator>丹尼尔·Y·崔</dc:creator><dc:creator>德纳·海耶斯</dc:creator><dc:creator>塞缪尔·梅德曼</dc:creator><dc:creator>内哈尔·达杜克</dc:creator><dc:creator>吉尔·雅各布斯</dc:creator><dc:creator>安娜·施穆克勒</dc:creator><dc:creator>杰弗里·S·伯杰</dc:creator><dc:creator>杰曼袖口</dc:creator><dc:creator>大卫·雷赫</dc:creator><dc:creator>米切尔·李</dc:creator><dc:creator>罗伯特·唐尼诺</dc:creator><dc:creator>纳撒尼尔·R·斯米洛维茨</dc:creator><dc:date>2023-09-21</dc:date><dc:source>循环</dc:source><dc:title>现有的非门控 CT 冠状动脉钙可预测接受非心脏手术的患者的手术风险 (ENCORES)</dc:title><dc:identifier>下午:37732454</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.064398</dc:identifier></item><item><title>当代心脏肿瘤学中的心血管成像：美国心脏协会的科学声明</title><link/>https://pubmed.ncbi.nlm.nih.gov/37732422/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230921221526&amp;v=2.17.9.post6+86293ac<description>癌症治疗的进步极大地提高了患者的生存率，目前已包括近 2000 万患者，并且还在不断增加。然而，与特定癌症治疗相关的心血管毒性会对癌症患者的预后产生不利影响。心血管成像的进步巩固了癌症患者生存率的关键作用。检测、监测和预测癌症患者心脏风险的稳健方法。然而，分散的评估导致缺乏…… </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 9 月 21 日。doi：10.1161/CIR.0000000000001174。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">癌症治疗的进步极大地提高了患者的生存率，目前已包括近 2000 万患者，并且还在不断增加。然而，与特定癌症治疗相关的心血管毒性会对癌症患者的预后产生不利影响。心血管成像的进步巩固了癌症患者生存率的关键作用。检测、监测和预测癌症患者心脏风险的稳健方法。然而，分散的评估导致对当代癌症治疗（例如免疫治疗、靶向治疗或生物治疗）中影像学的最佳使用缺乏共识。同样，现有的孤立的临床前和临床研究对心血管成像在癌症护理中多种模式的有效性提供了不完整的见解。本科学声明的目的是确定心血管成像在癌症治疗和生存环境中的证据的当前状态，以及提出新颖的最佳方法学方法，为心血管成像在未来临床试验和注册中的应用提供信息。我们还提出了一种基于证据的综合方法，在常规临床环境中使用心血管成像。这份科学声明总结并澄清了现有证据，同时提供新兴抗癌疗法时代多模态心血管成像的最佳使用指南。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37732422/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230921221526&v=2.17.9.post6+86293ac">37732422</a> | DOI： <a href=https://doi.org/10.1161/CIR.0000000000001174>10.1161/CIR.0000000000001174</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37732422</guid><pubDate> Thu, 21 Sep 2023 06:00:00 -0400</pubDate><dc:creator>丹尼尔·艾迪生</dc:creator><dc:creator>托马斯·内兰</dc:creator><dc:creator>安娜巴拉克</dc:creator><dc:creator>玛丽埃尔·谢勒-克罗斯比</dc:creator><dc:creator>托奇·M·奥库萨</dc:creator><dc:creator>胡安·C·普拉纳</dc:creator><dc:creator>克里恩·W·雷丁</dc:creator><dc:creator>维维安尼·R·塔奎蒂</dc:creator><dc:creator>埃里克·杨</dc:creator><dc:creator>弗拉德·G·扎哈</dc:creator><dc:creator>美国心脏协会心血管放射学和干预委员会；临床心脏病学委员会心脏肿瘤学委员会和基因组与精准医学委员会；以及心血管和中风护理委员会</dc:creator><dc:date>2023-09-21</dc:date><dc:source>循环</dc:source><dc:title>当代心脏肿瘤学中的心血管成像：美国心脏协会的科学声明</dc:title><dc:identifier>下午：37732422</dc:identifier><dc:identifier>号码：10.1161/CIR.0000000000001174</dc:identifier></item><item><title> CHIP 在 HF 中的作用：预后作用和细胞内在效应</title><link/>https://pubmed.ncbi.nlm.nih.gov/37730906/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230921221526&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Nat Rev Cardiol。2023 年 9 月 20 日。doi：10.1038/s41569-023-00942-7。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37730906/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230921221526&v=2.17.9.post6+86293ac">37730906</a> | DOI： <a href=https://doi.org/10.1038/s41569-023-00942-7>10.1038/s41569-023-00942-7</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37730906</guid><pubDate> Thu, 21 Sep 2023 06:00:00 -0400</pubDate><dc:creator>卡琳娜·黄</dc:creator><dc:date>2023-09-21</dc:date><dc:source> 《自然》评论、心脏病学</dc:source><dc:title>CHIP 在 HF 中的作用：预后作用和细胞内在效应</dc:title><dc:identifier>下午：37730906</dc:identifier><dc:identifier> doi:10.1038/s41569-023-00942-7</dc:identifier></item><item><title>答复：乙酰唑胺治疗急性失代偿性心力衰竭</title><link/>https://pubmed.ncbi.nlm.nih.gov/37730297/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230921221526&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 9 月 26 日；82(13):e113.doi:10.1016/j.jacc.2023.07.016。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37730297/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230921221526&v=2.17.9.post6+86293ac">37730297</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.07.016>10.1016/j.jacc.2023.07.016</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37730297</guid><pubDate> Wed, 20 Sep 2023 06:00:00 -0400</pubDate><dc:creator>弗雷德里克·H·韦尔布鲁格</dc:creator><dc:creator>彼得·马滕斯</dc:creator><dc:creator>威尔弗里德·穆伦斯</dc:creator><dc:date>2023-09-20</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>答复：乙酰唑胺治疗急性失代偿性心力衰竭</dc:title><dc:identifier>下午:37730297</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.07.016</dc:identifier></item><item><title>乙酰唑胺治疗急性失代偿性心力衰竭</title><link/>https://pubmed.ncbi.nlm.nih.gov/37730296/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230921221526&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 9 月 26 日；82(13):e111.doi:10.1016/j.jacc.2023.06.048。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37730296/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230921221526&v=2.17.9.post6+86293ac">37730296</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.06.048>10.1016/j.jacc.2023.06.048</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37730296</guid><pubDate> Wed, 20 Sep 2023 06:00:00 -0400</pubDate><dc:creator>拉姆达斯·G·派</dc:creator><dc:date>2023-09-20</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>乙酰唑胺治疗急性失代偿性心力衰竭</dc:title><dc:identifier>下午:37730296</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.06.048</dc:identifier></item><item><title>社会经济背景对幼儿期心血管健康促进的影响</title><link/>https://pubmed.ncbi.nlm.nih.gov/37730295/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230921221526&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 9 月 26 日；82(13):1377-1379.doi:10.1016/j.jacc.2023.07.014。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37730295/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230921221526&v=2.17.9.post6+86293ac">37730295</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.07.014>10.1016/j.jacc.2023.07.014</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37730295</guid><pubDate> Wed, 20 Sep 2023 06:00:00 -0400</pubDate><dc:creator>阿玛亚·德·科斯-甘多伊</dc:creator><dc:creator>格洛丽亚·桑托斯·贝尼特</dc:creator><dc:creator>帕特里夏·博德加</dc:creator><dc:creator>豪尔赫·巴克斯特</dc:creator><dc:creator>拉克尔·迪亚兹-穆尼奥斯</dc:creator><dc:creator>克里斯托弗·希尔</dc:creator><dc:creator>伊莎贝尔·卡瓦哈尔</dc:creator><dc:creator>卡洛斯·佩拉</dc:creator><dc:creator>罗德里戈·费尔南德斯·希门尼斯</dc:creator><dc:creator>瓦伦丁·福斯特</dc:creator><dc:date>2023-09-20</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>社会经济背景对幼儿期心血管健康促进的影响</dc:title><dc:identifier>下午：37730295</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.07.014</dc:identifier></item><item><title>心血管护理伦理：行动呼吁</title><link/>https://pubmed.ncbi.nlm.nih.gov/37730294/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230921221526&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 9 月 26 日；82(13):1373-1376.doi:10.1016/j.jacc.2023.08.004。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37730294/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230921221526&v=2.17.9.post6+86293ac">37730294</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.08.004>10.1016/j.jacc.2023.08.004</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37730294</guid><pubDate> Wed, 20 Sep 2023 06:00:00 -0400</pubDate><dc:creator>豪尔赫·R·阿莱格里亚</dc:creator><dc:creator>B哈德利·威尔逊</dc:creator><dc:creator>R·斯科特·赖特</dc:creator><dc:date>2023-09-20</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>心血管护理伦理：行动呼吁</dc:title><dc:identifier>下午:37730294</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.08.004</dc:identifier></item><item><title>评估治疗效果的广义成对比较：JACC 本周评论主题</title><link/>https://pubmed.ncbi.nlm.nih.gov/37730293/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230921221526&amp;v=2.17.9.post6+86293ac<description>首次事件发生时间复合终点分析在评估心血管临床试验中的治疗效果方面存在众所周知的缺点，它不能充分描述治疗的临床益处，因为事件的严重程度、随时间重复的事件以及临床情况。无法考虑相关的非生存结果。广义成对比较 (GPC) 方法通过包含最能捕捉到的任何数量和类型的结果，增加了定义主要终点的灵活性...... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 9 月 26 日；82(13):1360-1372.doi:10.1016/j.jacc.2023.06.047。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">首次事件发生时间复合终点分析在评估心血管临床试验中的治疗效果方面存在众所周知的缺点，它不能充分描述治疗的临床益处，因为事件的严重程度、随时间重复的事件以及临床情况。不能考虑相关的非生存结局。广义配对比较 (GPC) 方法通过包括与标准护理相比最能体现治疗临床获益的任何数量和类型的结局，增加了定义主要终点的灵活性。临床上重要的结局，包括出血严重程度、干预次数和生活质量，可以很容易地整合到单一分析中。GPC 中的治疗效果可以用净治疗获益、成功几率或获胜率来表示。这篇综述为以下方面提供了指导：使用 GPC 以及选择治疗效果测量来分析和报告心血管试验。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37730293/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230921221526&v=2.17.9.post6+86293ac">37730293</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.06.047>10.1016/j.jacc.2023.06.047</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37730293</guid><pubDate> Wed, 20 Sep 2023 06:00:00 -0400</pubDate><dc:creator>约翰·维贝克</dc:creator><dc:creator>米凯尔·德巴克</dc:creator><dc:creator>简·韦尔夫特</dc:creator><dc:creator>塞缪尔·萨尔瓦乔</dc:creator><dc:creator>马可·瓦尔吉米利</dc:creator><dc:creator>帕斯卡·弗兰克斯</dc:creator><dc:creator>马克·比斯</dc:creator><dc:creator>埃德加·布伦纳</dc:creator><dc:date>2023-09-20</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>评估治疗效果的广义成对比较：JACC 本周评论主题</dc:title><dc:identifier>下午:37730293</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.06.047</dc:identifier></item><item><title>无传统可改变危险因素的患者冠状动脉粥样硬化的临床路径：JACC 最先进的综述</title><link/>https://pubmed.ncbi.nlm.nih.gov/37730292/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230921221526&amp;v=2.17.9.post6+86293ac<description>降低标准可改变心血管危险因素 (SMuRF) 的发生率和患病率对于解决全球冠状动脉疾病 (CAD) 负担至关重要。然而，尽管没有 SMuRF，仍有大量个体出现冠状动脉粥样硬化。无 SMuRF 的心肌梗塞患者据观察，与患有至少 1 SMuRF 的亲属相比，其早期死亡率出乎意料地更高。这些患者最佳管理的证据是…… </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 9 月 26 日；82(13):1343-1359.doi:10.1016/j.jacc.2023.06.045。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">降低标准可改变心血管危险因素 (SMuRF) 的发生率和患病率对于解决全球冠状动脉疾病 (CAD) 负担至关重要。然而，尽管没有 SMuRF，仍有大量个体出现冠状动脉粥样硬化。无 SMuRF 的心肌梗塞患者据观察，与至少 1 个 SMuRF 的学分相比，这些患者的早期死亡率出乎意料地更高。缺乏对这些患者进行最佳治疗的证据。我们组建了一个国际多学科团队，为无 SMuRF CAD 患者开发基于证据的临床路径。应用了改良的德尔菲法。由此产生的途径确认了潜在的动脉粥样硬化和真正的 SMuRFless 状态，确保基于证据的二级预防，并考虑对不太典型的贡献者进行额外的测试和干预。这条专门针对以前被忽视的 CAD 人群的途径，并附有登记册，旨在通过加强对循证二级预防的遵守以及对观察到的可改变风险因素的额外诊断来改善结果。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37730292/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230921221526&v=2.17.9.post6+86293ac">37730292</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.06.045>10.1016/j.jacc.2023.06.045</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37730292</guid><pubDate> Wed, 20 Sep 2023 06:00:00 -0400</pubDate><dc:creator>杰玛·无花果树</dc:creator><dc:creator>斯蒂芬·T·弗农</dc:creator><dc:creator>贾森·哈默</dc:creator><dc:creator>迈克尔·P·格雷</dc:creator><dc:creator>克莱尔·阿诺特</dc:creator><dc:creator>埃里克·巴乔尔</dc:creator><dc:creator>詹尼·巴尔沙</dc:creator><dc:creator>大卫·布里格</dc:creator><dc:creator>亚历克斯·布朗</dc:creator><dc:creator>大卫·塞勒马杰</dc:creator><dc:creator>基思·M·查农</dc:creator><dc:creator>尼古拉斯·WS·周</dc:creator><dc:creator>詹姆斯·JH·庄</dc:creator><dc:creator>克拉拉·周</dc:creator><dc:creator>彼得·西斯图利</dc:creator><dc:creator>帕特里克·埃利诺</dc:creator><dc:creator>斯图尔特·M·格里夫</dc:creator><dc:creator>托马斯·J·古兹克</dc:creator><dc:creator>埃米尔·哈格斯特罗姆</dc:creator><dc:creator>艾丽西亚·詹金斯</dc:creator><dc:creator>加里·詹宁斯</dc:creator><dc:creator>安东尼·C·基奇</dc:creator><dc:creator>凯瑟琳·科特</dc:creator><dc:creator>伦纳德·克里萨里德斯</dc:creator><dc:creator>妈妈妈妈</dc:creator><dc:creator>罗克珊娜·迈赫兰</dc:creator><dc:creator>彼得·J·米克尔</dc:creator><dc:creator>普拉迪普·纳塔拉詹</dc:creator><dc:creator>根岸一明</dc:creator><dc:creator>约翰·奥沙利文</dc:creator><dc:creator>桑杰·帕特尔</dc:creator><dc:creator>彼得·J·帕萨尔蒂斯</dc:creator><dc:creator>朱莉·雷德芬</dc:creator><dc:creator>菲利普·G·施泰格</dc:creator><dc:creator>大卫·沙利文</dc:creator><dc:creator>约翰·桑德斯特伦</dc:creator><dc:creator>比尔吉特·沃格尔</dc:creator><dc:creator>安德鲁·威尔逊</dc:creator><dc:creator>黄丹尼斯</dc:creator><dc:creator>迪帕克·巴特</dc:creator><dc:creator>贾森·C·科瓦西奇</dc:creator><dc:creator>斯蒂芬·尼科尔斯</dc:creator><dc:creator>面向 CAD 协作者的 CRE</dc:creator><dc:date> 2023-09-20</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>无传统可改变危险因素的患者冠状动脉粥样硬化的临床路径：JACC 最先进的综述</dc:title><dc:identifier>下午:37730292</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.06.045</dc:identifier></item><item><title>先天性心脏病的慢性药物负担很重要</title><link/>https://pubmed.ncbi.nlm.nih.gov/37730291/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230921221526&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 9 月 26 日；82(13):1341-1342.doi:10.1016/j.jacc.2023.07.017。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37730291/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230921221526&v=2.17.9.post6+86293ac">37730291</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.07.017>10.1016/j.jacc.2023.07.017</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37730291</guid><pubDate> Wed, 20 Sep 2023 06:00:00 -0400</pubDate><dc:creator>玛丽·B·泰勒</dc:creator><dc:date>2023-09-20</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>先天性心脏病的慢性药物负担很重要</dc:title><dc:identifier>下午:37730291</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.07.017</dc:identifier></item><item><title>儿童医疗补助受益人心脏手术后的慢性药物负担</title><link/>https://pubmed.ncbi.nlm.nih.gov/37730290/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230921221526&amp;v=2.17.9.post6+86293ac<description>结论：接受心脏手术的儿童在整个童年时期都会经历较高的药物负担。了解慢性药物使用情况可以告知婴儿（儿科医生和亚专科医生）和政策制定者，并最终了解护理这一医学复杂人群的价值。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 9 月 26 日；82(13):1331-1340.doi:10.1016/j.jacc.2023.06.046。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：先天性心脏病是最常见且资源密集型的出生缺陷。随着先天性心脏病儿童越来越多地存活到幼儿期之后，了解纵向疾病负担势在必行。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：本研究的目的是调查纽约州儿科医疗补助参与者的长期门诊处方药使用情况和支出，比较接受心脏手术的儿童（心脏参与者）和一般儿科人群。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：这是一项使用纽约州先天性心脏手术纵向结果和资源利用数据库合作组织（2006-2019）对所有年龄&lt;18岁的医疗补助参与者进行的回顾性队列研究。主要结果是每人每年的慢性药物总量，每 100 人每年使用 ≥1 种和 ≥3 种药物的参与者，以及每人每年的药物支出。我们描述并比较了心脏参与者和一般儿科人群之间的结果。在心脏参与者中，多变量回归检查了结果与临床特征之间的关联。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：我们纳入了 5,459 名接受过心脏手术的儿童（32,131 人年）和 450 万名未接受心脏手术的儿童（2200 万人年）。每 10 名接受心脏手术的儿童中，超过 4 名使用了 ≥ 1 种慢性药物，而大约每 10 名儿童中就有 1 名未接受过心脏手术。与非心脏参与者相比，每人每年的心脏药物支出高出 10 倍。在心脏参与者中，疾病严重程度与长期药物使用相关；使用率在婴儿中最高；然而，近一半的青少年使用≥1种慢性药物。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：接受心脏手术的儿童在整个童年时期都会经历较高的药物负担。了解慢性药物使用情况可以告知婴儿（儿科医生和亚专科医生）和政策制定者，并最终了解护理这一医学复杂人群的价值。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37730290/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230921221526&v=2.17.9.post6+86293ac">37730290</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.06.046>10.1016/j.jacc.2023.06.046</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37730290</guid><pubDate> Wed, 20 Sep 2023 06:00:00 -0400</pubDate><dc:creator>乔伊斯·L·胡</dc:creator><dc:creator>凯瑟琳·纳什</dc:creator><dc:creator>凯西·德拉甘</dc:creator><dc:creator>莎拉·克鲁克</dc:creator><dc:creator>马修·尼德尔</dc:creator><dc:creator>史蒂芬·库克</dc:creator><dc:creator>爱德华·汉南</dc:creator><dc:creator>马歇尔·雅各布斯</dc:creator><dc:creator>安德鲁·B·戈德斯通</dc:creator><dc:creator>克里斯托弗·J·佩蒂特</dc:creator><dc:creator>罗伯特·文森特</dc:creator><dc:creator>凯瑟琳·沃尔什·斯彭豪威尔</dc:creator><dc:creator>拉尔夫·莫斯卡</dc:creator><dc:creator>TK 苏希尔·库马尔</dc:creator><dc:creator>尼尔·德韦吉安</dc:creator><dc:creator>史蒂文·卡梅尼尔</dc:creator><dc:creator>乔治·M·阿尔菲里斯</dc:creator><dc:creator>迈克尔·F·斯沃茨</dc:creator><dc:creator>大卫·迈耶</dc:creator><dc:creator>艾琳·保罗</dc:creator><dc:creator>简·W·纽伯格</dc:creator><dc:creator>约翰·比林斯</dc:creator><dc:creator>马修·M·戴维斯</dc:creator><dc:creator>布雷特·R·安德森</dc:creator><dc:creator>纽约州先天性心脏外科纵向结果和资源利用合作组织 (CHS-COLOUR)</dc:creator><dc:date> 2023-09-20</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>儿童医疗补助受益人心脏手术后的慢性药物负担</dc:title><dc:identifier>下午:37730290</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.06.046</dc:identifier></item><item><title>定期测量中青年 eGFR 和蛋白尿的时间</title><link/>https://pubmed.ncbi.nlm.nih.gov/37730289/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230921221526&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 9 月 26 日；82(13):1328-1330.doi:10.1016/j.jacc.2023.07.013。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37730289/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230921221526&v=2.17.9.post6+86293ac">37730289</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.07.013>10.1016/j.jacc.2023.07.013</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37730289</guid><pubDate> Wed, 20 Sep 2023 06:00:00 -0400</pubDate><dc:creator>丹尼尔·杜普雷兹</dc:creator><dc:creator>大卫·R·雅各布斯</dc:creator><dc:date>2023-09-20</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>定期测量中青年 eGFR 和蛋白尿的时间</dc:title><dc:identifier>下午:37730289</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.07.013</dc:identifier></item><item><title>年轻人的肾功能受损和主要心血管事件</title><link/>https://pubmed.ncbi.nlm.nih.gov/37730288/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230921221526&amp;v=2.17.9.post6+86293ac<description>结论：在年轻人中，eGFR 低于年龄预期值与 MACE 和 MACE+ 风险升高相关，需要进行适合年龄的风险分层、主动监测和及时干预。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 9 月 26 日；82(13):1316-1327.doi:10.1016/j.jacc.2023.07.012。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：年轻人（18-39 岁）的心血管 (CV) 疾病呈上升趋势。肾功能亚临床下降（即估计肾小球滤过率 [eGFR] 是否高于当前慢性肾病阈值但低于年龄）预期值）与心血管风险升高的相关性尚不清楚。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：本研究的目的是探讨患有主要不良心血管事件 (MACE) 和 MACE 合并心力衰竭 (MACE+) 的年轻人亚临床 eGFR 降低与年龄相关性。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：使用加拿大安大略省的关联省级医疗保健数据集（2008 年 1 月至 2021 年 3 月）对 870 万人（360 万人年龄在 18-39 岁）进行回顾性队列研究。Cox 模型用于检查分类之间的关联eGFR (50-120 mL/min/1.73 m <sup>2</sup> ) 与 MACE（心血管死亡、急性冠脉综合征和缺血性中风的首位）和 MACE+，根据年龄分层（18-39、40-49 和 50-65 岁） ）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在研究队列中（平均年龄 41.3 岁；平均 eGFR 104.2 mL/min/1.73 m <sup>2</sup> ；中位随访时间 9.2 年），早在 eGFR &lt;80 时就观察到 MACE 和 MACE+ 的相对风险逐步增加年轻人中的 mL/min/1.73 m <sup>2</sup> （例如，对于 MACE，eGFR 70-79 mL/min/1.73 m <sup>2</sup> ，年龄 18-30 岁：每 1,000 人年 2.37 次事件 [HR：1.31；95% CI： 40-49 岁：每 1,000 人年 6.26 起事件 [HR：1.09；95% CI：1.06-1.12]；50-65 岁：每 1,000 人年 14.9 起事件 [HR：1.07；95% CI：1.05-1.08 ]). 每个 MACE 组成部分和其他分析（根据过去的 CV 疾病分层，考虑指数蛋白尿，并使用重复的 eGFR 测量）的结果仍然存在。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：在年轻人中，eGFR 低于年龄预期值与 MACE 和 MACE+ 风险升高相关，需要进行适合年龄的风险分层、主动监测和及时干预。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37730288/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230921221526&v=2.17.9.post6+86293ac">37730288</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.07.012>10.1016/j.jacc.2023.07.012</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37730288</guid><pubDate> Wed, 20 Sep 2023 06:00:00 -0400</pubDate><dc:creator>朱奈德·侯赛因</dc:creator><dc:creator>哈里斯·伊姆西罗维奇</dc:creator><dc:creator>马克·坎尼</dc:creator><dc:creator>爱德华·G·克拉克</dc:creator><dc:creator>梅根·埃利奥特</dc:creator><dc:creator>彼得罗·拉瓦尼</dc:creator><dc:creator>彼得·塔努塞普特罗</dc:creator><dc:creator>阿尤布·阿克巴里</dc:creator><dc:creator>格雷戈里·L·洪德默</dc:creator><dc:creator>蒂姆·拉姆齐</dc:creator><dc:creator>纳夫迪普·唐格里</dc:creator><dc:creator>格雷格·诺尔</dc:creator><dc:creator>曼尼什·M·苏德</dc:creator><dc:date>2023-09-20</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>年轻人的肾功能受损和主要心血管事件</dc:title><dc:identifier>下午：37730288</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.07.012</dc:identifier></item><item><title>心脏手术后围术期心肌损伤/梗塞：诊断标准需要改变</title><link/>https://pubmed.ncbi.nlm.nih.gov/37730287/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230921221526&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 9 月 26 日；82(13):1313-1315.doi:10.1016/j.jacc.2023.08.001。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37730287/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230921221526&v=2.17.9.post6+86293ac">37730287</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.08.001>10.1016/j.jacc.2023.08.001</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37730287</guid><pubDate> Wed, 20 Sep 2023 06:00:00 -0400</pubDate><dc:creator> P·J·德弗罗</dc:creator><dc:creator>理查德·惠特洛克</dc:creator><dc:creator>安德烈·拉米</dc:creator><dc:date>2023-09-20</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>心脏手术后围术期心肌损伤/梗塞：诊断标准需要改变</dc:title><dc:identifier>下午：37730287</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.08.001</dc:identifier></item><item><title>高敏心肌肌钙蛋白 T 与心脏手术后 30 天和 5 年死亡率的关系</title><link/>https://pubmed.ncbi.nlm.nih.gov/37730286/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230921221526&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: PMI reflected by perioperative hs-cTnT release is associated with the expected 30-day mortality but not 5-year mortality. Postoperative hs-cTnT cutoffs to identify survival-relevant PMI are higher than suggested in current definitions. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol. 2023 Sep 26;82(13):1301-1312. doi: 10.1016/j.jacc.2023.07.011.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: The relevance of perioperative myocardial injury (PMI) after cardiac surgery for 30-day mortality and long-term survival remains to be determined. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> OBJECTIVES: This study assessed the association of PMI after cardiac surgery, reflected by postoperative troponin release, with 30-day mortality and long-term survival after: 1) coronary artery bypass grafting (CABG); 2) isolated aortic valve replacement (AVR) surgery; and 3) all other cardiac surgeries. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: A consecutive cohort of 8,292 patients undergoing cardiac surgery with serial perioperative high-sensitivity cardiac troponin T (hs-cTnT) measurements was retrospectively analyzed. The relationship between postoperative hs-cTnT release and 30-day mortality or 5-year mortality was analyzed after adjustment with EuroSCORE II using a Cox proportional hazards model. hs-cTnT thresholds for 30-day and 5-year mortality were determined for isolated CABG (32.3%), AVR (14%), and other cardiac surgery (53.8%). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: High postoperative hs-cTnT levels were associated with higher 30-day mortality but not 5-year mortality. In CABG, median peak concentration of postoperative hs-cTnT was 1,044 ng/L, in AVR it was 502 ng/L, and in other cardiac surgery it was 1,110 ng/L. hs-cTnT thresholds defining mortality-associated PMI were as follows: for CABG, 2,385 ng/L (170× the upper reference limit of normal in a seemingly healthy population [URL]); for AVR, 568 ng/L (41× URL); and for other cardiac procedures, 1,873 ng/L (134× URL). hs-cTnT levels above the cutoffs resulted in an HR for 30-day mortality for CABG of 12.56 (P &lt; 0.001), for AVR of 4.44 (P = 0.004), and for other cardiac surgery of 3.97 (P &lt; 0.001). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: PMI reflected by perioperative hs-cTnT release is associated with the expected 30-day mortality but not 5-year mortality. Postoperative hs-cTnT cutoffs to identify survival-relevant PMI are higher than suggested in current definitions.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37730286/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230921221526&v=2.17.9.post6+86293ac">37730286</a> | DOI: <a href=https://doi.org/10.1016/j.jacc.2023.07.011>10.1016/j.jacc.2023.07.011</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37730286</guid><pubDate> Wed, 20 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Leo Pölzl</dc:creator><dc:creator> Clemens Engler</dc:creator><dc:creator> Philipp Sterzinger</dc:creator><dc:creator> Ronja Lohmann</dc:creator><dc:creator> Felix Nägele</dc:creator><dc:creator> Jakob Hirsch</dc:creator><dc:creator> Michael Graber</dc:creator><dc:creator> Jonas Eder</dc:creator><dc:creator> Sebastian Reinstadler</dc:creator><dc:creator> Nikolay Sappler</dc:creator><dc:creator> Juliane Kilo</dc:creator><dc:creator> Ivan Tancevski</dc:creator><dc:creator> Sebastian Bachmann</dc:creator><dc:creator> Hannes Abfalterer</dc:creator><dc:creator> Elfriede Ruttmann-Ulmer</dc:creator><dc:creator> Hanno Ulmer</dc:creator><dc:creator> Andrea Griesmacher</dc:creator><dc:creator> Samuel Heuts</dc:creator><dc:creator> Matthias Thielmann</dc:creator><dc:creator> Axel Bauer</dc:creator><dc:creator> Michael Grimm</dc:creator><dc:creator> Nikolaos Bonaros</dc:creator><dc:creator> Johannes Holfeld</dc:creator><dc:creator> Can Gollmann-Tepeköylü</dc:creator><dc:date> 2023-09-20</dc:date><dc:source> Journal of the American College of Cardiology</dc:source><dc:title> Association of High-Sensitivity Cardiac Troponin T With 30-Day and 5-Year Mortality After Cardiac Surgery</dc:title><dc:identifier> pmid:37730286</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.07.011</dc:identifier></item><item><title> Expanding Success of Mitral Transcatheter Edge-to-Edge Repair in Real-World Patients: And More Questions to Answer</title><link/> https://pubmed.ncbi.nlm.nih.gov/37730285/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230921221526&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol. 2023 Sep 26;82(13):1298-1300. doi: 10.1016/j.jacc.2023.08.002.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37730285/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230921221526&v=2.17.9.post6+86293ac">37730285</a> | DOI: <a href=https://doi.org/10.1016/j.jacc.2023.08.002>10.1016/j.jacc.2023.08.002</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37730285</guid><pubDate> Wed, 20 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Mathias Orban</dc:creator><dc:creator> Jörg Hausleiter</dc:creator><dc:date> 2023-09-20</dc:date><dc:source> Journal of the American College of Cardiology</dc:source><dc:title> Expanding Success of Mitral Transcatheter Edge-to-Edge Repair in Real-World Patients: And More Questions to Answer</dc:title><dc:identifier> pmid:37730285</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.08.002</dc:identifier></item><item><title> Transcatheter Edge-to-Edge Repair in 5,000 Patients With Secondary Mitral Regurgitation: COAPT Post-Approval Study</title><link/> https://pubmed.ncbi.nlm.nih.gov/37730284/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230921221526&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: This large, contemporary, real-world study reinforces the safety and effectiveness of the MitraClip System in patients with SMR, including those who met the COAPT or MITRA-FR RCT inclusion/exclusion criteria and patients excluded from the RCTs. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol. 2023 Sep 26;82(13):1281-1297. doi: 10.1016/j.jacc.2023.07.015.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: Real-world applicability of the COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation) randomized controlled trial (RCT) has been debated because of careful patient selection and the contrasting results of the MITRA-FR (Multicentre Study of Percutaneous Mitral Valve Repair MitraClip Device in Patients with Severe Secondary Mitral Regurgitation) RCT. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> OBJECTIVES: The COAPT-PAS (COAPT Post-Approval Study) was initiated to assess the safety and effectiveness of the MitraClip in patients with secondary mitral regurgitation (SMR). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: COAPT-PAS is a prospective, single-arm, observational study of 5,000 consecutive patients with SMR treated with the MitraClip at 406 US centers participating in the TVT (Transcatheter Valve Therapy) registry from 2019 to 2020. The 1-year outcomes from the COAPT-PAS full cohort and the COAPT-like and MITRA-FR-like subgroups who met RCT inclusion/exclusion criteria are reported. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Patients in the COAPT-PAS had more comorbidities, more severe HF and functional limitations, and less guideline-directed medical therapy than those in the COAPT or MITRA-FR RCTs. Patients in the COAPT-PAS full cohort and the COAPT-like (n = 991) and MITRA-FR-like (n = 917) subgroups achieved a 97.7% MitraClip implant rate, a similar and durable reduction of mitral regurgitation to ≤2+ at 1 year (90.7%, 89.7%, and 86.6%, respectively), a large improvement in quality of life at 1 year (Kansas City Cardiomyopathy Questionnaire +29 COAPT-PAS, +27 COAPT-like, and +33 MITRA-FR-like), faster procedure times, similar or lower clinical event rates compared with the RCTs&#39; MitraClip arms, and lower clinical event rates than the RCTs&#39; guideline-directed medical therapy only arms. One-year heart failure hospitalizations was 18.9% in COAPT-PAS, 19.7% in COAPT-like compared with 24.9% in COAPT-RCT, and 28.7% in COAPT-PAS-MITRA-FR-like compared with 47.4% in MITRA-FR-RCT. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: This large, contemporary, real-world study reinforces the safety and effectiveness of the MitraClip System in patients with SMR, including those who met the COAPT or MITRA-FR RCT inclusion/exclusion criteria and patients excluded from the RCTs.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37730284/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230921221526&v=2.17.9.post6+86293ac">37730284</a> | DOI: <a href=https://doi.org/10.1016/j.jacc.2023.07.015>10.1016/j.jacc.2023.07.015</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37730284</guid><pubDate> Wed, 20 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Kashish Goel</dc:creator><dc:creator> JoAnn Lindenfeld</dc:creator><dc:creator> Raj Makkar</dc:creator><dc:creator> Hursh Naik</dc:creator><dc:creator> Satya Atmakuri</dc:creator><dc:creator> Paul Mahoney</dc:creator><dc:creator> Michael A Morse</dc:creator><dc:creator> Vinod H Thourani</dc:creator><dc:creator> Pradeep Yadav</dc:creator><dc:creator> Wayne Batchelor</dc:creator><dc:creator> Jason Rogers</dc:creator><dc:creator> Brian Whisenant</dc:creator><dc:creator> Michael Rinaldi</dc:creator><dc:creator> James Hermiller</dc:creator><dc:creator> Brian R Lindman</dc:creator><dc:creator> Colin M Barker</dc:creator><dc:date> 2023-09-20</dc:date><dc:source> Journal of the American College of Cardiology</dc:source><dc:title> Transcatheter Edge-to-Edge Repair in 5,000 Patients With Secondary Mitral Regurgitation: COAPT Post-Approval Study</dc:title><dc:identifier> pmid:37730284</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.07.015</dc:identifier></item><item><title> Alzheimer&#39;s disease: From immunotherapy to immunoprevention</title><link/> https://pubmed.ncbi.nlm.nih.gov/37729908/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230921221526&amp;v=2.17.9.post6+86293ac<description> Recent Aβ-immunotherapy trials have yielded the first clear evidence that removing aggregated Aβ from the brains of symptomatic patients can slow the progression of Alzheimer&#39;s disease. The clinical benefit achieved in these trials has been modest, however, highlighting the need for both a deeper understanding of disease mechanisms and the importance of intervening early in the pathogenic cascade. An immunoprevention strategy for Alzheimer&#39;s disease is required that will integrate the findings... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 Sep 17:S0092-8674(23)00910-8. doi: 10.1016/j.cell.2023.08.021. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Recent Aβ-immunotherapy trials have yielded the first clear evidence that removing aggregated Aβ from the brains of symptomatic patients can slow the progression of Alzheimer&#39;s disease. The clinical benefit achieved in these trials has been modest, however, highlighting the need for both a deeper understanding of disease mechanisms and the importance of intervening early in the pathogenic cascade. An immunoprevention strategy for Alzheimer&#39;s disease is required that will integrate the findings from clinical trials with mechanistic insights from preclinical disease models to select promising antibodies, optimize the timing of intervention, identify early biomarkers, and mitigate potential side effects.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37729908/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230921221526&v=2.17.9.post6+86293ac">37729908</a> | DOI: <a href=https://doi.org/10.1016/j.cell.2023.08.021>10.1016/j.cell.2023.08.021</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37729908</guid><pubDate> Wed, 20 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Mathias Jucker</dc:creator><dc:creator> Lary C Walker</dc:creator><dc:date> 2023-09-20</dc:date><dc:source> Cell</dc:source><dc:title> Alzheimer&#39;s disease: From immunotherapy to immunoprevention</dc:title><dc:identifier> pmid:37729908</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.08.021</dc:identifier></item><item><title> Stepwise emergence of the neuronal gene expression program in early animal evolution</title><link/> https://pubmed.ncbi.nlm.nih.gov/37729907/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230921221526&amp;v=2.17.9.post6+86293ac<description> The assembly of the neuronal and other major cell type programs occurred early in animal evolution. We can reconstruct this process by studying non-bilaterians like placozoans. These small disc-shaped animals not only have nine morphologically described cell types and no neurons but also show coordinated behaviors triggered by peptide-secreting cells. We investigated possible neuronal affinities of these peptidergic cells using phylogenetics, chromatin profiling, and comparative single-cell... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 Sep 14:S0092-8674(23)00917-0. doi: 10.1016/j.cell.2023.08.027. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> The assembly of the neuronal and other major cell type programs occurred early in animal evolution. We can reconstruct this process by studying non-bilaterians like placozoans. These small disc-shaped animals not only have nine morphologically described cell types and no neurons but also show coordinated behaviors triggered by peptide-secreting cells. We investigated possible neuronal affinities of these peptidergic cells using phylogenetics, chromatin profiling, and comparative single-cell genomics in four placozoans. We found conserved cell type expression programs across placozoans, including populations of transdifferentiating and cycling cells, suggestive of active cell type homeostasis. We also uncovered fourteen peptidergic cell types expressing neuronal-associated components like the pre-synaptic scaffold that derive from progenitor cells with neurogenesis signatures. In contrast, earlier-branching animals like sponges and ctenophores lacked this conserved expression. Our findings indicate that key neuronal developmental and effector gene modules evolved before the advent of cnidarian/bilaterian neurons in the context of paracrine cell signaling.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37729907/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230921221526&v=2.17.9.post6+86293ac">37729907</a> | DOI: <a href=https://doi.org/10.1016/j.cell.2023.08.027>10.1016/j.cell.2023.08.027</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37729907</guid><pubDate> Wed, 20 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Sebastián R Najle</dc:creator><dc:creator> Xavier Grau-Bové</dc:creator><dc:creator> Anamaria Elek</dc:creator><dc:creator> Cristina Navarrete</dc:creator><dc:creator> Damiano Cianferoni</dc:creator><dc:creator> Cristina Chiva</dc:creator><dc:creator> Didac Cañas-Armenteros</dc:creator><dc:creator> Arrate Mallabiabarrena</dc:creator><dc:creator> Kai Kamm</dc:creator><dc:creator> Eduard Sabidó</dc:creator><dc:creator> Harald Gruber-Vodicka</dc:creator><dc:creator> Bernd Schierwater</dc:creator><dc:creator> Luis Serrano</dc:creator><dc:creator> Arnau Sebé-Pedrós</dc:creator><dc:date> 2023-09-20</dc:date><dc:source> Cell</dc:source><dc:title> Stepwise emergence of the neuronal gene expression program in early animal evolution</dc:title><dc:identifier> pmid:37729907</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.08.027</dc:identifier></item></channel></rss>